Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 117

Similar articles for PubMed (Select 14527633)

1.

Hyperinsulinemic diseases of civilization: more than just Syndrome X.

Cordain L, Eades MR, Eades MD.

Comp Biochem Physiol A Mol Integr Physiol. 2003 Sep;136(1):95-112. Review.

PMID:
14527633
2.

Insulin resistance, the insulin resistance syndrome, and cardiovascular disease.

Reaven GM.

Panminerva Med. 2005 Dec;47(4):201-10. Review.

PMID:
16489319
3.

Metformin therapy increases insulin-like growth factor binding protein-1 in hyperinsulinemic women with polycystic ovary syndrome.

Pawelczyk L, Spaczynski RZ, Banaszewska B, Duleba AJ.

Eur J Obstet Gynecol Reprod Biol. 2004 Apr 15;113(2):209-13.

PMID:
15063962
4.

[Molecular action of insulin-sensitizing agents].

Kacalska O, Krzyczkowska-Sendrakowska M, Milewicz T, Zabińska-Popiela M, Bereza T, Krzysiek-Maczka G, Krzysiek J.

Endokrynol Pol. 2005 May-Jun;56(3):308-13. Review. Polish.

PMID:
16350724
5.

Polycystic ovary syndrome and type 2 diabetes mellitus.

De Leo V, Musacchio MC, Morgante G, La Marca A, Petraglia F.

Minerva Ginecol. 2004 Feb;56(1):53-62. Review.

PMID:
14973410
6.

Prostate cancer prevention by nutritional means to alleviate metabolic syndrome.

Barnard RJ.

Am J Clin Nutr. 2007 Sep;86(3):s889-93. Review.

7.

Pathophysiology of insulin resistance in human disease.

Reaven GM.

Physiol Rev. 1995 Jul;75(3):473-86. Review.

PMID:
7624391
8.

Childhood obesity and insulin resistance.

Maclaren NK, Gujral S, Ten S, Motagheti R.

Cell Biochem Biophys. 2007;48(2-3):73-8.

PMID:
17709876
9.

Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities.

Resmini E, Minuto F, Colao A, Ferone D.

Acta Diabetol. 2009 Jun;46(2):85-95. doi: 10.1007/s00592-009-0112-9. Epub 2009 Mar 26. Review.

PMID:
19322513
10.

[Genetic aspects of polycystic ovary syndrome].

Jakubowski L.

Endokrynol Pol. 2005 May-Jun;56(3):285-93. Review. Polish.

PMID:
16350721
12.

[The metabolic syndrome. Part II: its mechanisms of development and its complications].

Pacholczyk M, Ferenc T, Kowalski J.

Postepy Hig Med Dosw (Online). 2008 Oct 16;62:543-58. Review. Polish.

13.

Increased insulin-like growth factor-I levels in women with polycystic ovary syndrome, and beneficial effects of metformin therapy.

Berker B, Emral R, Demirel C, Corapcioglu D, Unlu C, Kose K.

Gynecol Endocrinol. 2004 Sep;19(3):125-33.

PMID:
15697073
15.

Endometrium in PCOS: Implantation and predisposition to endocrine CA.

Giudice LC.

Best Pract Res Clin Endocrinol Metab. 2006 Jun;20(2):235-44. Review.

PMID:
16772154
16.

[Insulin-like growth factor-binding protein-1: a new biochemical marker of nonalcoholic fatty liver disease?].

Graffigna MN, Belli SH, de Larrañaga G, Fainboim H, Estepo C, Peres S, García N, Levalle O.

Acta Gastroenterol Latinoam. 2009 Mar;39(1):30-7. Spanish.

PMID:
19408737
17.

Insulin-like growth factor binding protein-2 (IGFBP-2) is a marker for the metabolic syndrome.

Heald AH, Kaushal K, Siddals KW, Rudenski AS, Anderson SG, Gibson JM.

Exp Clin Endocrinol Diabetes. 2006 Jul;114(7):371-6.

PMID:
16915540
18.

Energy balance, physical activity, and cancer risk.

Fair AM, Montgomery K.

Methods Mol Biol. 2009;472:57-88. doi: 10.1007/978-1-60327-492-0_3. Review.

PMID:
19107429
19.

Hemorheological aspects of the metabolic syndrome: markers of insulin resistance, obesity or hyperinsulinemia?

Brun JF, Aloulou I, Varlet-Marie E.

Clin Hemorheol Microcirc. 2004;30(3-4):203-9.

PMID:
15258344
20.

Subcutaneous adipocytes from obese hyperinsulinemic women with polycystic ovary syndrome exhibit normal insulin sensitivity but reduced maximal insulin responsiveness.

Lystedt E, Westergren H, Brynhildsen J, Lindh-Astrand L, Gustavsson J, Nystrom FH, Hammar M, Strålfors P.

Eur J Endocrinol. 2005 Dec;153(6):831-5.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk